TrialBlood advances2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Amy E DeZern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.